Latest Biotech News

Insilico Medicine, fresh from a Hong Kong IPO, signed an R&D collaboration with Servier valued at up to $888 million to discover oncology therapies using Insilico’s AI platforms. The agreement...

Hutchmed reported a Phase 3 success with sovleplenib in an autoimmune indication and said it will pursue a China filing based on the trial’s positive primary endpoint. The result revives an asset...

Industry reflection on cell therapies intensified after a spate of clinical disappointments and safety concerns in solid‑tumor CAR‑T programs. A candid analysis recounts patient tragedies,...

A U.S. Court of Appeals affirmed a lower‑court injunction preventing the National Institutes of Health from imposing a 15% cap on indirect cost reimbursement for grantees, ruling the NIH's...

Amgen agreed to acquire Oxford spinout Dark Blue Therapeutics in a deal worth up to $840 million, adding a preclinical small-molecule degrader that targets MLLT1/3 and other protein-degradation...

Alumis reported positive top-line results from two Phase 3 trials of envudeucitinib (envu), a selective oral TYK2 inhibitor, meeting co-primary and multiple secondary endpoints in patients with...

Federal health officials moved to reduce the number of vaccines universally recommended for U.S. children from 17 to 11, a policy shift attributed to directives from the White House and HHS. The...

Eli Lilly expanded its partnership with Nimbus Therapeutics under a multi-year research and license agreement that could be worth up to $1.3 billion in milestones and royalties. Lilly will apply...

Arrowhead Pharmaceuticals released interim human data showing its RNAi obesity candidates produced meaningful fat loss in small cohorts, including when combined with Lilly’s tirzepatide...

AI-driven drug discovery continued to attract large pharma partnerships: Insilico Medicine signed an agreement with Servier reportedly worth up to $888 million focused on oncology R&D, while...

Moderna submitted regulatory applications for its mRNA seasonal influenza vaccine, mRNA-1010, to agencies in the U.S., Europe, Canada and Australia, seeking approval for use in people aged 50 and...

Zenas Biopharma announced that obexelimab met the primary endpoint in a Phase 3 trial for immunoglobulin G4-related disease (IgG4-RD) and plans a BLA submission; however, market reaction was...

Stereotaxis received U.S. FDA clearance for its Magic magnetic interventional ablation catheter, marking the device maker’s first proprietary robotic ablation catheter authorized for use in the...

Pfizer and Cartography Biosciences announced a collaboration to identify tumor-selective antigens using Cartography’s ATLAS and SUMMIT discovery platforms. The multi-option deal includes about $65...

Federal health officials announced an abrupt reduction in the number of vaccines the Centers for Disease Control and Prevention will universally recommend for children, cutting the routine list...

Eli Lilly expanded its metabolic pipeline by signing a multiyear discovery and exclusive worldwide license with Nimbus Therapeutics focused on an oral obesity program, with total value potential...

Arrowhead Pharmaceuticals released early clinical data showing its RNAi candidates produced meaningful fat loss when combined with Lilly’s tirzepatide (Zepbound), including disproportionate...

Amgen agreed to acquire U.K.-based Dark Blue Therapeutics in a deal worth up to $840 million, adding a preclinical small molecule degrader aimed at MLLT1/3 to its oncology pipeline. Amgen said the...

Sanofi struck a definitive agreement to acquire Dynavax Technologies for approximately $2.2 billion in cash, adding Dynavax’s adult hepatitis B vaccine (HEPLISAV‑B) and a Phase I/II shingles...

Insilico Medicine signed a multiyear R&D collaboration with Servier valued at up to $888 million to discover and develop oncology therapeutics using Insilico’s AI discovery platform. The agreement...